{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:47:35Z","timestamp":1782841655106,"version":"3.54.5"},"reference-count":22,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n Prostate cancer is the second leading cause of cancer-related mortality in men worldwide. Prostate-specific membrane antigen (PSMA)\u2013targeted radioligand therapy (RLT) has emerged as a theranostic strategy for metastatic castration-resistant prostate cancer (mCRPC), with [\n 177<\/jats:sup>\n Lu]Lu-PSMA-617 demonstrating survival benefits in the VISION trial. However, clinical responses are heterogeneous, and resistance mechanisms remain poorly understood. Liquid biopsy (LBx), particularly circulating tumor DNA (ctDNA), may provide a minimally invasive approach to assess tumor heterogeneity, monitor response, and detect emerging resistance.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The LOOPS (Liquid Biopsy as a Biomarker in Patients Treated with PSMA Radioligand Therapy) study aims to prospectively investigate the prognostic and predictive value of ctDNA in patients undergoing PSMA RLT.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n LOOPS is a prospective, multicenter observational biomarker trial recruiting 100 patients with mCRPC eligible for PSMA RLT across 3 Bavarian cancer research centers in Germany. Patients will undergo up to 6 cycles of [\n 177<\/jats:sup>\n Lu]Lu-PSMA-617. Blood samples for ctDNA analysis will be collected longitudinally (at baseline and after cycles 1, 2, 4, and 6) and processed according to standardized protocols. Imaging with PSMA positron emission tomography\u2013computed tomography and clinical and biochemical data will be systematically collected. The primary end points are the prognostic and predictive value of baseline ctDNA for treatment response, defined by imaging- and prostate-specific antigen (PSA)\u2013based response criteria after 2 cycles of PSMA RLT. Predictive performance will be evaluated using receiver operating characteristic analyses, including the determination of optimal ctDNA cutoffs, sensitivity, specificity, positive and negative predictive values, and multivariable logistic regression models adjusting for relevant clinical confounders. Secondary end points assess the concordance and correlation between ctDNA dynamics, systematically assessed PSMA positron emission tomography\u2013computed tomography response, and PSA changes, as well as associations between ctDNA and clinical or laboratory (eg, age, Gleason score, and other) characteristics at baseline and during follow-up. Exploratory analyses will investigate early molecular response patterns based on short-term ctDNA changes and will characterize clonal dynamics and potential resistance mechanisms under therapy.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study has been funded by the German Research Foundation (Deutsche Forschungsgemeinschaft) since July 2025. Patient recruitment has already commenced, and in January 2026, a total of 63 patients have been enrolled. Analysis of LBx samples was initiated in January 2026, while recruitment and data collection are ongoing.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The LOOPS study will provide the first prospective, systematic evaluation of ctDNA as a biomarker in PSMA RLT. By integrating molecular, imaging, and clinical data, it aims to clarify the role of LBx in response monitoring and the early identification of resistance. The results could pave the way toward personalized therapeutic strategies in mCRPC.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/86737","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:27:57Z","timestamp":1777537677000},"page":"e86737-e86737","source":"Crossref","is-referenced-by-count":0,"title":["Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2610-2059","authenticated-orcid":false,"given":"Kerstin","family":"Michalski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3377-032X","authenticated-orcid":false,"given":"Theo","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Jedamzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3526-8601","authenticated-orcid":false,"given":"Marieke","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9313-9356","authenticated-orcid":false,"given":"Aleksander","family":"Kosmala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-2153","authenticated-orcid":false,"given":"Isabel","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0924-4332","authenticated-orcid":false,"given":"Mika","family":"Bauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9832-3963","authenticated-orcid":false,"given":"Lena","family":"Reichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8560-395X","authenticated-orcid":false,"given":"Luisa","family":"Amann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Liebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6447-0613","authenticated-orcid":false,"given":"Andreas","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-644X","authenticated-orcid":false,"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7536-2207","authenticated-orcid":false,"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-8766","authenticated-orcid":false,"given":"Rainer","family":"Claus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"2","key":"R1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"R2","first-page":"81","volume":"3","author":"Silver","journal-title":"Clin Cancer Res"},{"issue":"2","key":"R3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/pros.10319","article-title":"Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene","volume":"58","author":"O\u2019Keefe","journal-title":"Prostate"},{"issue":"12","key":"R4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","journal-title":"N Engl J Med"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231179309","article-title":"Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Kostos","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"R6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2967\/jnumed.120.256263","article-title":"Mechanisms of resistance to prostate-specific membrane antigen-targeted radioligand therapy in a mouse model of prostate cancer","volume":"62","author":"Stuparu","journal-title":"J Nucl Med"},{"issue":"15","key":"R7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157614","article-title":"Dissecting tumor heterogeneity by liquid biopsy-a comparative analysis of post-mortem tissue and pre-mortem liquid biopsies in solid neoplasias","volume":"26","author":"M\u00f6gele","journal-title":"Int J Mol Sci"},{"issue":"13","key":"R8","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.3390\/cancers14133272","article-title":"Liquid biopsy in prostate cancer management-current challenges and future perspectives","volume":"14","author":"Crocetto","journal-title":"Cancers (Basel)"},{"issue":"12","key":"R9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx118","article-title":"Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer","volume":"109","author":"Wyatt","journal-title":"J Natl Cancer Inst"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00014","article-title":"Evaluation of commercial circulating tumor DNA test in metastatic prostate cancer","volume":"3","author":"Taavitsainen","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"R11","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00259-024-06698-7","article-title":"Comparison of discovery rates and prognostic utility of [Ga]Ga-PSMA-11 PET\/CT and circulating tumor DNA in prostate cancer-a cross-sectional study","volume":"51","author":"Kluge","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10276","key":"R12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","journal-title":"Lancet"},{"issue":"8","key":"R13","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1038\/s41591-025-03704-9","article-title":"Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial","volume":"31","author":"Kwan","journal-title":"Nat Med"},{"issue":"11","key":"R14","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","article-title":"Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","volume":"27","author":"Tukachinsky","journal-title":"Clin Cancer Res"},{"issue":"11","key":"R15","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2967\/jnumed.123.266167","article-title":"Prediction of resistance to Lu-PSMA therapy by assessment of baseline circulating tumor DNA biomarkers","volume":"64","author":"Sartor","journal-title":"J Nucl Med"},{"issue":"11","key":"R16","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1007\/s00259-025-07280-5","article-title":"Genomic instability is associated with response to [\u00b9\u2077\u2077Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis","volume":"52","author":"Kluge","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"R17","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.7150\/thno.44556","article-title":"Molecular analysis of circulating tumor cells of metastatic castration-resistant prostate cancer patients receiving Lu-PSMA-617 radioligand therapy","volume":"10","author":"Kessel","journal-title":"Theranostics"},{"issue":"11","key":"R18","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/pros.24549","article-title":"PSMA-heterogeneity in metastatic castration-resistant prostate cancer: circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy","volume":"83","author":"Derlin","journal-title":"Prostate"},{"issue":"12","key":"R19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","journal-title":"J Clin Oncol"},{"issue":"11","key":"R20","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2967\/jnumed.121.263072","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","journal-title":"J Nucl Med"},{"issue":"1","key":"R21","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","journal-title":"Radiology"},{"issue":"3","key":"R22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1515\/labmed-2023-0156","article-title":"Concept and feasibility of the Augsburg Longitudinal Plasma Study (ALPS) \u2013 a prospective trial for comprehensive liquid biopsy-based longitudinal monitoring of solid cancer patients","volume":"48","author":"Sommer","journal-title":"J Lab Med"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e86737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:14:28Z","timestamp":1782839668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e86737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":22,"URL":"https:\/\/doi.org\/10.2196\/86737","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"v15i2e86737"}}